Business Wire
-
bit.bio Announces First Project Within Multi-Year Collaboration Agreement With The Michael J. Fox Foundation (MJFF) To Generate Human Cell Products For Research And Drug Discovery In Parkinson’s Disease
3/5/2024
bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).
-
AnHeart Therapeutics And Innovent Announce China’s NMPA Has Accepted Second New Drug Application For Taletrectinib For First-Line Treatment Of ROS1-Positive Lung Cancer
3/4/2024
AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, and Innovent Biologics, Inc. (“Innovent”) a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted a second New Drug Application (NDA) for taletrectinib, a
-
Microsoft And 1910 Genetics Partner To Build The Infrastructure Layer For Drug Discovery And Development Using AI And High-Performance Computing
2/29/2024
1910 Genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, today announced a new five-year commercial agreement and go-to-market collaboration with Microsoft to harness advanced artificial intelligence (AI) and next-generation, high-performance computing (HPC) to reverse 70 years of declining pharmaceutical R&D productivity.
-
Everest Medicines And Kezar Life Sciences Receive IND Approval From China NMPA For PALIZADE Trial In Lupus Nephritis
2/26/2024
Everest Medicines and Kezar Life Sciences, Inc. announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).
-
Ligand Partner Eisai Receives Approval In Japan For Injection Formulation Of Antiepileptic Drug Fycompa
2/22/2024
Ligand Pharmaceuticals Incorporated today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
-
Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK In Lupus Nephritis
2/22/2024
Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK (also known as AB-101) for the treatment of lupus nephritis (LN) in combination with rituximab or obinutuzumab.
-
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted By US FDA For IO-202 (Anti-LILRB4) For The Treatment Of Chronic Myelomonocytic Leukemia (CMML)
2/21/2024
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S.
-
For The First Time, Quantum-Enhanced Generative AI Generates Viable Cancer Drug Candidates
2/20/2024
Zapata Computing, Inc. (“Zapata AI” or the “Company”), the Industrial Generative AI company, today announced that its scientists, in collaboration with Insilico Medicine, the University of Toronto, and St. Jude Children’s Research Hospital have demonstrated the first instance of a generative model running on quantum hardware outperforming state-of-the-art classical models in generating viable cancer drug candidates.
-
Atara Biotherapeutics Announces Submission Of Investigational New Drug Application For ATA3219 For Treatment Of Lupus Nephritis
2/14/2024
Atara Biotherapeutics, Inc. a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]).
-
GSK Exercises Option To License Elsie Biotechnologies’ Discovery Platform To Find And Develop Novel Oligonucleotides
2/14/2024
Elsie Biotechnologies, Inc. announced today that GSK plc has exercised its option to a non-exclusive license to Elsie’s discovery platform, following a successful outcome of the research collaboration, announced in July 2023, to explore the platform capabilities.